Literature DB >> 33646466

7-ketocholesterol induces endothelial-mesenchymal transition and promotes fibrosis: implications in neovascular age-related macular degeneration and treatment.

Haibo Wang1, Aniket Ramshekar1, Eric Kunz1, M Elizabeth Hartnett2.   

Abstract

Oxidized cholesterols and lipids accumulate in Bruch's membrane in age-related macular degeneration (AMD). It remains unknown what causal relationship exists between these substances and AMD pathophysiology. We addressed the hypothesis that a prevalent form, 7-ketocholesterol (7KC), promotes choroidal endothelial cell (CEC) migration and macular neovascularization in AMD. Compared to control, 7KC injection caused 40% larger lectin-stained lesions, but 70% larger lesions measured by optical coherence tomography one week after laser-injury. At two weeks, 7KC-injected eyes had 86% larger alpha smooth muscle actin (αSMA)-labeled lesions and more collagen-labeling than control. There was no difference in cell death. 7KC-treated RPE/choroids had increased αSMA but decreased VE-cadherin. Compared to control-treated CECs, 7KC unexpectedly reduced endothelial VE-cadherin, CD31 and VEGFR2 and increased αSMA, fibroblast activation protein (FAP) and transforming growth factor beta (TGFβ). Inhibition of TGFβ receptor-mediated signaling by SB431542 abrogated 7KC-induced loss of endothelial and increase in mesenchymal proteins in association with decreased transcription factor, SMAD3. Knockdown of SMAD3 partially inhibited 7KC-mediated loss of endothelial proteins and increase in αSMA and FAP. Compared to control, 7KC-treatment of CECs increased Rac1GTP and migration, and both were inhibited by the Rac1 inhibitor; however, CECs treated with 7KC had reduced tube formation. These findings suggest that 7KC, which increases in AMD and with age, induces mesenchymal transition in CECs making them invasive and migratory, and causing fibrosis in macular neovascularization. Further studies to interfere with this process may reduce fibrosis and improve responsiveness to anti-VEGF treatment in non-responsive macular neovascularization in AMD.
© 2021. The Author(s), under exclusive licence to Springer Nature B.V. part of Springer Nature.

Entities:  

Keywords:  7-ketocholesterol; Age-related macular degeneration; Choroidal endothelial cells; Endothelial-mesenchymal transition; Macular fibrosis; Non-responsive (or unresponsive) neovascular AMD

Mesh:

Substances:

Year:  2021        PMID: 33646466      PMCID: PMC8865553          DOI: 10.1007/s10456-021-09770-0

Source DB:  PubMed          Journal:  Angiogenesis        ISSN: 0969-6970            Impact factor:   10.658


  33 in total

1.  Do we need a new classification for choroidal neovascularization in age-related macular degeneration?

Authors:  K Bailey Freund; Sandrine A Zweifel; Michael Engelbert
Journal:  Retina       Date:  2010-10       Impact factor: 4.256

2.  Prevalence, Risk, and Genetic Association of Reticular Pseudodrusen in Age-related Macular Degeneration: Age-Related Eye Disease Study 2 Report 21.

Authors:  Amitha Domalpally; Elvira Agrón; Jeong W Pak; Tiarnan D Keenan; Fredrick L Ferris; Traci E Clemons; Emily Y Chew
Journal:  Ophthalmology       Date:  2019-07-29       Impact factor: 12.079

3.  Correlations between Choriocapillaris Flow Deficits around Geographic Atrophy and Enlargement Rates Based on Swept-Source OCT Imaging.

Authors:  Marie Thulliez; Qinqin Zhang; Yingying Shi; Hao Zhou; Zhongdi Chu; Luis de Sisternes; Mary K Durbin; William Feuer; Giovanni Gregori; Ruikang K Wang; Philip J Rosenfeld
Journal:  Ophthalmol Retina       Date:  2019-02-06

4.  The Evolution of Fibrosis and Atrophy and Their Relationship with Visual Outcomes in Asian Persons with Neovascular Age-Related Macular Degeneration.

Authors:  Chui Ming Gemmy Cheung; Dilraj S Grewal; Kelvin Yi Chong Teo; Alfred Gan; Aditi Mohla; Usha Chakravarthy; Tien Yin Wong; Glenn J Jaffe
Journal:  Ophthalmol Retina       Date:  2019-06-12

5.  Alterations in Extracellular Matrix/Bruch's Membrane Can Cause the Activation of the Alternative Complement Pathway via Tick-Over.

Authors:  Rosario Fernandez-Godino
Journal:  Adv Exp Med Biol       Date:  2018       Impact factor: 2.622

6.  Dietary folate, B vitamins, genetic susceptibility and progression to advanced nonexudative age-related macular degeneration with geographic atrophy: a prospective cohort study.

Authors:  Bénédicte M J Merle; Rachel E Silver; Bernard Rosner; Johanna M Seddon
Journal:  Am J Clin Nutr       Date:  2016-04       Impact factor: 7.045

7.  Heterotypic RPE-choroidal endothelial cell contact increases choroidal endothelial cell transmigration via PI 3-kinase and Rac1.

Authors:  Lynda J Peterson; Erika S Wittchen; Pete Geisen; Keith Burridge; M Elizabeth Hartnett
Journal:  Exp Eye Res       Date:  2006-12-23       Impact factor: 3.467

Review 8.  Age-related macular degeneration: genetics and biology coming together.

Authors:  Lars G Fritsche; Robert N Fariss; Dwight Stambolian; Gonçalo R Abecasis; Christine A Curcio; Anand Swaroop
Journal:  Annu Rev Genomics Hum Genet       Date:  2014-04-16       Impact factor: 8.929

Review 9.  Regulation of signaling events involved in the pathophysiology of neovascular AMD.

Authors:  Haibo Wang; M Elizabeth Hartnett
Journal:  Mol Vis       Date:  2016-02-27       Impact factor: 2.367

Review 10.  Oxidative stress, hypoxia, and autophagy in the neovascular processes of age-related macular degeneration.

Authors:  Janusz Blasiak; Goran Petrovski; Zoltán Veréb; Andrea Facskó; Kai Kaarniranta
Journal:  Biomed Res Int       Date:  2014-02-23       Impact factor: 3.411

View more
  2 in total

Review 1.  Regulation of Rac1 Activation in Choroidal Endothelial Cells: Insights into Mechanisms in Age-Related Macular Degeneration.

Authors:  Aniket Ramshekar; Haibo Wang; M Elizabeth Hartnett
Journal:  Cells       Date:  2021-09-14       Impact factor: 7.666

2.  Effect of Withanolide A on 7-Ketocholesterol Induced Cytotoxicity in hCMEC/D3 Brain Endothelial Cells.

Authors:  Sandra Soh; Wei-Yi Ong
Journal:  Cells       Date:  2022-01-28       Impact factor: 6.600

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.